vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Pagaya Technologies Ltd. (PGY). Click either name above to swap in a different company.

Pagaya Technologies Ltd. is the larger business by last-quarter revenue ($321.0M vs $168.4M, roughly 1.9× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 16.5%). Over the past eight quarters, Pagaya Technologies Ltd.'s revenue compounded faster (16.4% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Pagaya Technologies is an Israeli-American financial technology company based in New York City. The company evaluates loan applications using artificial intelligence (AI) with the aim of modernizing credit checks. The company has been listed on the New York Stock Exchange since 2022. According to its own figures, Pagaya had assessed loan applications with a volume of around US$2.6 trillion and brokered a cumulative loan volume of around US$28 billion by 2024. Its customers are mainly banks an...

ESPR vs PGY — Head-to-Head

Bigger by revenue
PGY
PGY
1.9× larger
PGY
$321.0M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+127.3% gap
ESPR
143.7%
16.5%
PGY
Faster 2-yr revenue CAGR
PGY
PGY
Annualised
PGY
16.4%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
PGY
PGY
Revenue
$168.4M
$321.0M
Net Profit
$34.3M
Gross Margin
40.8%
Operating Margin
50.6%
24.8%
Net Margin
10.7%
Revenue YoY
143.7%
16.5%
Net Profit YoY
114.4%
EPS (diluted)
$0.32
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
PGY
PGY
Q4 25
$168.4M
$321.0M
Q3 25
$87.3M
$339.9M
Q2 25
$82.4M
$317.7M
Q1 25
$65.0M
$282.7M
Q4 24
$69.1M
$275.7M
Q3 24
$51.6M
$249.3M
Q2 24
$73.8M
$242.6M
Q1 24
$137.7M
$237.0M
Net Profit
ESPR
ESPR
PGY
PGY
Q4 25
$34.3M
Q3 25
$-31.3M
$22.5M
Q2 25
$-12.7M
$16.7M
Q1 25
$-40.5M
$7.9M
Q4 24
$-237.9M
Q3 24
$-29.5M
$-67.5M
Q2 24
$-61.9M
$-74.8M
Q1 24
$61.0M
$-21.2M
Gross Margin
ESPR
ESPR
PGY
PGY
Q4 25
40.8%
Q3 25
41.0%
Q2 25
39.7%
Q1 25
40.9%
Q4 24
42.6%
Q3 24
40.2%
Q2 24
40.0%
Q1 24
38.9%
Operating Margin
ESPR
ESPR
PGY
PGY
Q4 25
50.6%
24.8%
Q3 25
-11.4%
23.5%
Q2 25
8.6%
17.8%
Q1 25
-34.0%
16.9%
Q4 24
-6.4%
11.5%
Q3 24
-31.0%
9.0%
Q2 24
3.5%
2.1%
Q1 24
52.5%
3.2%
Net Margin
ESPR
ESPR
PGY
PGY
Q4 25
10.7%
Q3 25
-35.9%
6.6%
Q2 25
-15.4%
5.2%
Q1 25
-62.2%
2.8%
Q4 24
-86.3%
Q3 24
-57.2%
-27.1%
Q2 24
-83.9%
-30.8%
Q1 24
44.3%
-9.0%
EPS (diluted)
ESPR
ESPR
PGY
PGY
Q4 25
$0.32
$0.40
Q3 25
$-0.16
$0.23
Q2 25
$-0.06
$0.20
Q1 25
$-0.21
$0.10
Q4 24
$-0.14
$-3.36
Q3 24
$-0.15
$-0.93
Q2 24
$-0.33
$-1.04
Q1 24
$0.34
$-0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
PGY
PGY
Cash + ST InvestmentsLiquidity on hand
$167.9M
$235.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$480.0M
Total Assets
$465.9M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
PGY
PGY
Q4 25
$167.9M
$235.3M
Q3 25
$92.4M
$218.3M
Q2 25
$86.1M
$183.0M
Q1 25
$114.6M
$186.8M
Q4 24
$144.8M
$187.9M
Q3 24
$144.7M
$147.1M
Q2 24
$189.3M
$233.6M
Q1 24
$226.6M
$274.5M
Total Debt
ESPR
ESPR
PGY
PGY
Q4 25
Q3 25
Q2 25
Q1 25
$317.9M
Q4 24
Q3 24
$230.2M
Q2 24
$232.6M
Q1 24
$235.0M
Stockholders' Equity
ESPR
ESPR
PGY
PGY
Q4 25
$-302.0M
$480.0M
Q3 25
$-451.4M
$438.3M
Q2 25
$-433.5M
$366.8M
Q1 25
$-426.2M
$335.5M
Q4 24
$-388.7M
$326.5M
Q3 24
$-370.2M
$462.3M
Q2 24
$-344.2M
$526.0M
Q1 24
$-294.3M
$626.8M
Total Assets
ESPR
ESPR
PGY
PGY
Q4 25
$465.9M
$1.5B
Q3 25
$364.0M
$1.5B
Q2 25
$347.1M
$1.4B
Q1 25
$324.0M
$1.3B
Q4 24
$343.8M
$1.3B
Q3 24
$314.1M
$1.4B
Q2 24
$352.3M
$1.5B
Q1 24
$373.1M
$1.5B
Debt / Equity
ESPR
ESPR
PGY
PGY
Q4 25
Q3 25
Q2 25
Q1 25
0.95×
Q4 24
Q3 24
0.50×
Q2 24
0.44×
Q1 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
PGY
PGY
Operating Cash FlowLast quarter
$45.2M
$79.8M
Free Cash FlowOCF − Capex
$76.7M
FCF MarginFCF / Revenue
23.9%
Capex IntensityCapex / Revenue
0.0%
1.0%
Cash ConversionOCF / Net Profit
2.33×
TTM Free Cash FlowTrailing 4 quarters
$224.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
PGY
PGY
Q4 25
$45.2M
$79.8M
Q3 25
$-4.3M
$67.0M
Q2 25
$-31.4M
$57.4M
Q1 25
$-22.6M
$34.4M
Q4 24
$-35.0M
$27.9M
Q3 24
$-35.3M
$-7.1M
Q2 24
$-7.2M
$9.3M
Q1 24
$53.8M
$17.7M
Free Cash Flow
ESPR
ESPR
PGY
PGY
Q4 25
$76.7M
Q3 25
$63.8M
Q2 25
$53.5M
Q1 25
$30.7M
Q4 24
$23.9M
Q3 24
$-35.5M
$-11.3M
Q2 24
$-7.3M
$4.9M
Q1 24
$53.8M
$12.6M
FCF Margin
ESPR
ESPR
PGY
PGY
Q4 25
23.9%
Q3 25
18.8%
Q2 25
16.9%
Q1 25
10.8%
Q4 24
8.7%
Q3 24
-68.7%
-4.6%
Q2 24
-9.9%
2.0%
Q1 24
39.0%
5.3%
Capex Intensity
ESPR
ESPR
PGY
PGY
Q4 25
0.0%
1.0%
Q3 25
0.0%
1.0%
Q2 25
0.0%
1.2%
Q1 25
0.0%
1.3%
Q4 24
0.0%
1.4%
Q3 24
0.3%
1.7%
Q2 24
0.1%
1.8%
Q1 24
0.1%
2.2%
Cash Conversion
ESPR
ESPR
PGY
PGY
Q4 25
2.33×
Q3 25
2.97×
Q2 25
3.44×
Q1 25
4.36×
Q4 24
Q3 24
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

PGY
PGY

Network AI Fees$287.4M90%
Financial Service$33.6M10%

Related Comparisons